- Companies
- China Everbright
China Everbright Valuation Multiples
China Everbright is valued at $1.2B as of October 2026, a 12.4x revenue multiple. In the last 12 months, China Everbright revenue was $377M.
China Everbright Overview
About China Everbright
China Everbright Ltd is an investment management firm based predominantly in Hong Kong. The company's core activity includes investing in long-term investment vehicles to secure capital appreciation for its investors. Its investment portfolio is comprised of unlisted equity securities, equity derivatives, start-up, and development-stage companies and long-term equity. The company's operating segments include Fund Management Business and Principal Investments Business. Geographically, it generates maximum revenue from Mainland China.
Founded
1972
HQ
Employees
242
Website
Sectors
Financials (LTM)
EV
$4.7B
Valuation Multiples
Start free trialChina Everbright Financials
China Everbright reported last 12-month revenue of $377M.
In the same LTM period, China Everbright generated had net loss of ($228M).
Revenue (LTM)
China Everbright P&L
In the most recent fiscal year, China Everbright reported revenue of $209M and net income of ($245M).
China Everbright is unprofitable as of last fiscal year, with net margin of (117%).
Financial data powered by Morningstar, Inc.
China Everbright Stock Performance
China Everbright has current market cap of $1.2B, and enterprise value of $4.7B.
Market Cap Evolution
China Everbright's stock price is $0.73.
China Everbright share price decreased by 10.1% in the last 30 days, and by 44.0% in the last year.
China Everbright has an EPS (earnings per share) of $-0.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7B | $1.2B | -3.2% | -10.1% | -2.2% | -44.0% | $-0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChina Everbright Valuation Multiples
China Everbright trades at 12.4x EV/Revenue multiple.
EV / Revenue (LTM)
China Everbright Financial Valuation Multiples
As of October 16, 2026, China Everbright has market cap of $1.2B and EV of $4.7B.
China Everbright has a P/E ratio of (5.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified China Everbright Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


China Everbright Margins & Growth Rates
China Everbright decreased revenue by 5% and net profit by 10% in the last fiscal year.
In the most recent fiscal year, China Everbright reported net margin of (117%).
China Everbright Margins
China Everbright Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
China Everbright Operational KPIs
China Everbright's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $1.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
China Everbright Competitors
China Everbright competitors include Next Generation Technology Group, Ratos, Tetragon Financial Group, Patria Private Equity, Oakley Capital, Waha Capital, Amanat, Syncona, Antin Infrastructure Partners and Molten Ventures.
Most China Everbright public comparables operate across PE & VC.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $95M | $29M | 13.5x | 13.1x | 43.9x | 67.6x | |||
| $1.9B | $151M | 1.0x | 0.9x | 12.0x | 5.0x | |||
| - | - | - | - | - | - | |||
| $163M | - | 8.1x | - | - | - | |||
| $90M | - | 14.8x | - | - | - | |||
| $67M | - | 17.3x | 5.8x | - | - | |||
| $254M | $103M | 4.1x | - | 10.2x | - | |||
| $76M | - | 13.2x | 15.2x | - | - | |||
This data is available for Pro users. Sign up to see all China Everbright competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by China Everbright
China Everbright has acquired 2 companies to date.
Last acquisition by China Everbright was on May 13th 2016. China Everbright acquired Beijing Huichen Nursing Home Management Co., Ltd. for undisclosed valuation.
Latest Acquisitions by China Everbright
| Description | Beijing Huichen Nursing Home Management Co., Ltd. is a healthcare provider specializing in elderly care, geriatric treatment, rehabilitation, and community services. Operating through www.huichenlife.com, the company manages nursing facilities and delivers comprehensive support for senior living across Beijing and surrounding areas. | Burke E. Porter Machinery Company is a manufacturer of vehicle test systems including end-of-line equipment, dynamometers, and tire and wheel assembly systems supplied to major OEMs worldwide. Grand Rapids, Michigan-headquartered for 50 years, the firm pioneered the first fully electric DVT roll/brake machine and leads in automotive and heavy-duty testing innovations. Products support quality assurance in production lines for cars, trucks, and commercial vehicles. |
| HQ Country | ||
| HQ City | Beijing | Grand Rapids, MI |
| Deal Date | 13 May 2016 | 22 Oct 2014 |
| Valuation | undisclosed | $90M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all China Everbright acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by China Everbright
China Everbright has invested in 42 companies to date.
Latest investment by China Everbright was on July 28th 2026. China Everbright invested in Ractigen Therapeutics in their $31M Undisclosed stage round (EV/Revenue multiple available to Pro users).
Latest Investments by China Everbright
| Description | Ractigen Therapeutics is a San Francisco-headquartered biotech firm advancing RNA activation therapies to reactivate silenced genes in oncology and neurodegeneration. Its lead candidates target EZH2 and p21 genes using synthetic saRNAs delivered via lipid nanoparticles. Founded in 2016 from UCSF research, Ractigen advances clinical trials for liver cancer and holds patents on RNAa platforms licensed from the university. The pipeline includes programs for Alzheimer's partnered with academic labs. | Topband Huachuang is a membrane material technology developer. Topband Huachuang conducts research and development of special separation membrane materials used in new energy, semiconductor, and coal chemical fields. | YoungEn Technology is a Chinese firm developing automated production equipment and intelligent manufacturing solutions for industrial assembly lines. | KYinno is an oncology drug development company specializing in immune-oncology therapies. Beijing-based with US operations, it provides preclinical services including humanized mouse models for PD-1 and CAR-T testing. KYinno operates a 20,000-square-foot facility supporting IND-enabling studies. | |
| HQ Country | |||||
| HQ City | Nantong | Nantong | - | Beijing | |
| Deal Date | 28 Jul 2026 | 25 May 2026 | 7 Jan 2026 | 15 Dec 2025 | |
| Round | Undisclosed stage | Series C | Series B | Series B | |
| Raised | $31M | $15M | undisclosed | $36M | |
| Investors | Shenzhen Guozhong Venture Capital Management; SND Financial Holdings; IDG Capital; Jolmo Capital; Win-Win Capital; Longmen Capital; China Everbright | Yibin Gangxin Asset Management; Hong Kong Trust Asset Management; Chuannan Fund; Zero2IPO; China Everbright | China Everbright | Beijing E-town International Investment & Development; Beijing Yizhuang Investment Holding; Jinyi Fuxin; Yuanhui Chuangyi; BioTrack Capital; Tianjin Renai Capital; Beijing Medical and Health Industry Investment Fund; China Everbright | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all China Everbright investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout China Everbright
| When was China Everbright founded? | China Everbright was founded in 1972. |
| Where is China Everbright headquartered? | China Everbright is headquartered in Hong Kong. |
| How many employees does China Everbright have? | As of today, China Everbright has over 242 employees. |
| Is China Everbright publicly listed? | Yes, China Everbright is a public company listed on HKEX. |
| What is the stock symbol of China Everbright? | China Everbright trades under 00165 ticker. |
| When did China Everbright go public? | China Everbright went public in 1973. |
| Who are competitors of China Everbright? | China Everbright main competitors include Next Generation Technology Group, Ratos, Tetragon Financial Group, Patria Private Equity, Oakley Capital, Waha Capital, Amanat, Syncona, Antin Infrastructure Partners, Molten Ventures. |
| What is the current market cap of China Everbright? | China Everbright's current market cap is $1.2B. |
| What is the current revenue of China Everbright? | China Everbright's last 12 months revenue is $377M. |
| What is the current revenue growth of China Everbright? | China Everbright revenue growth (NTM/LTM) is (39%). |
| What is the current EV/Revenue multiple of China Everbright? | Current revenue multiple of China Everbright is 12.4x. |
| Is China Everbright profitable? | No, China Everbright is not profitable. |
| What is the current net income of China Everbright? | China Everbright's last 12 months net income is ($228M). |
| How many companies China Everbright has acquired to date? | As of October 2026, China Everbright has acquired 2 companies. |
| What was the largest acquisition by China Everbright? | $90M acquisition of Burke E. Porter Machinery on 22nd October 2014 was the largest M&A China Everbright has done to date. |
| What companies China Everbright acquired? | China Everbright acquired Burke E. Porter Machinery and Beijing Huichen Nursing Home Management Co., Ltd.. |
| In how many companies China Everbright has invested to date? | As of October 2026, China Everbright has invested in 42 companies. |
| In what companies China Everbright invested in? | China Everbright invested in iQIYI, Suning Finance, NIO, NetEase Cloud Music, Miaopai, Wish, ESR, China UnionPay Merchant Services, Terminus Technologies, Yijiupi, Mevion Medical Systems, Arctic Green Energy, Googut Wine & Spirits, Yinuo Pharmaceutical, Guangzhou Innogen Pharma, Dt Dream, IASO Biotherapeutics, TrustDecision, Amcare Women's and Children's Hospital, MicroTech Medical, and 22 other companies. |
See public comps similar to China Everbright
Lists including China Everbright
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




